Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: Results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up

Daniel J. Wallace, Caroline Gordon, Vibeke Strand, Kathryn Hobbs, Michelle Petri, Kenneth Kalunian, Frederic Houssiau, Paul P. Tak, David A. Isenberg, Lexy Kelley, Brian Kilgallen, Anna N. Barry, William A. Wegener, David M. Goldenberg

Research output: Contribution to journalArticlepeer-review

87 Scopus citations

Fingerprint

Dive into the research topics of 'Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: Results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology

Keyphrases

Neuroscience